These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 16670205)

  • 1. A multicentre randomised phase II study of carboplatin in combination with gemcitabine at standard rate or fixed dose rate infusion in patients with advanced stage non-small-cell lung cancer.
    Soo RA; Wang LZ; Tham LS; Yong WP; Boyer M; Lim HL; Lee HS; Millward M; Liang S; Beale P; Lee SC; Goh BC
    Ann Oncol; 2006 Jul; 17(7):1128-33. PubMed ID: 16670205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I trial of fixed dose-rate gemcitabine in combination with carboplatin in chemonaive advanced non-small-cell lung cancer: a Cancer Therapeutics Research Group study.
    Soo RA; Lim HL; Wang LZ; Lee HS; Millward MJ; Tok LT; Lee SC; Lehnert M; Goh BC
    Cancer Chemother Pharmacol; 2003 Aug; 52(2):153-8. PubMed ID: 12750842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of gemcitabine and carboplatin in patients with advanced non-small-cell lung cancer.
    Wang LR; Huang MZ; Zhang GB; Xu N; Wu XH
    Cancer Chemother Pharmacol; 2007 Sep; 60(4):601-7. PubMed ID: 17549479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy and relationship between peak concentration and toxicity profile of fixed-dose-rate gemcitabine plus carboplatin in patients with advanced non-small-cell lung cancer.
    Wang L; Wu X; Huang M; Cai J; Xu N; Liu J
    Cancer Chemother Pharmacol; 2007 Jul; 60(2):211-8. PubMed ID: 17124596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic study of gemcitabine, given as prolonged infusion at fixed dose rate, in combination with cisplatin in patients with advanced non-small-cell lung cancer.
    Caffo O; Fallani S; Marangon E; Nobili S; Cassetta MI; Murgia V; Sala F; Novelli A; Mini E; Zucchetti M; Galligioni E
    Cancer Chemother Pharmacol; 2010 May; 65(6):1197-202. PubMed ID: 20140616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gemcitabine in brief versus prolonged low-dose infusion, both combined with carboplatin for advanced non-small cell lung cancer.
    Beniwal SK; Patel KM; Shukla S; Parikh BJ; Shah S; Patel A
    Indian J Cancer; 2012; 49(2):202-8. PubMed ID: 23107971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized phase II trial evaluating standard (50 mg/min) versus low (10 mg/min) infusion duration of gemcitabine as first-line treatment in advanced non-small-cell lung cancer patients who are not eligible for platinum-based chemotherapy.
    Cappuzzo F; Novello S; De Marinis F; Selvaggi G; Scagliotti GV; Barbieri F; Maur M; Papi M; Pasquini E; Bartolini S; Marini L; Crinò L
    Lung Cancer; 2006 Jun; 52(3):319-25. PubMed ID: 16630670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized phase II study comparing two schedules of the 21-day regimen of gemcitabine and carboplatin in advanced non-small cell lung cancer.
    Surmont V; Aerts JG; van Klaveren RJ; Tournoy K; Tan KY; Vernhout RM; Schmitz PI; Legrand C; Hoogsteden HC; van Meerbeeck JP
    Oncology; 2010; 78(3-4):267-70. PubMed ID: 20523087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I trial of gemcitabine and carboplatin in metastatic non-small-cell lung cancer: a Groupe Français de Pneumo-Cancérologie Study.
    Thomas P; Robinet G; Ferri-Dessens RM; Léna H; Gouva S; Vernejoux JM; Kleisbauer JP
    Lung Cancer; 2002 May; 36(2):191-8. PubMed ID: 11955654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of low-dose gemcitabine in 6-hour infusion and carboplatin is a favorable option for patients in poor performance status with advanced non-small cell lung cancer.
    Wu ZY; Guan HH; Lin ZX; Yang HK; Zhou L; Cai QC
    J Chemother; 2014 Oct; 26(5):306-11. PubMed ID: 24075685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized Phase II trial of paclitaxel and carboplatin followed by gemcitabine switch-maintenance therapy versus gemcitabine and carboplatin followed by gemcitabine continuation-maintenance therapy in previously untreated advanced non-small cell lung cancer.
    Minami S; Kijima T; Shiroyama T; Okafuji K; Hirashima T; Uchida J; Imamura F; Osaki T; Nakatani T; Ogata Y; Yamamoto S; Namba Y; Otsuka T; Tachibana I; Komuta K; Kawase I
    BMC Res Notes; 2013 Jan; 6():3. PubMed ID: 23281805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemcitabine in brief versus prolonged low-dose infusion, both combined with cisplatin, for advanced non-small cell lung cancer: a randomized phase II clinical trial.
    Zwitter M; Kovac V; Smrdel U; Vrankar M; Zadnik V
    J Thorac Oncol; 2009 Sep; 4(9):1148-55. PubMed ID: 19546818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose-finding, pharmacokinetic and phase II study of docetaxel in combination with gemcitabine in patients with inoperable non-small cell lung cancer.
    Rebattu P; Quantin X; Ardiet C; Morere JF; Azarian MR; Schuller-Lebeau MP; Pujol JL
    Lung Cancer; 2001; 33(2-3):277-87. PubMed ID: 11551423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II study of biweekly gemcitabine and carboplatin in completely resected stage IB-IIIA non-small cell lung cancer.
    Sakurai R; Tomizawa Y; Yoshii A; Miura Y; Tsurumaki H; Kaira K; Sunaga N; Kawashima O; Hisada T; Yamada M; Saito R
    Cancer Chemother Pharmacol; 2018 Jan; 81(1):103-109. PubMed ID: 29124327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer.
    Grønberg BH; Bremnes RM; Fløtten O; Amundsen T; Brunsvig PF; Hjelde HH; Kaasa S; von Plessen C; Stornes F; Tollåli T; Wammer F; Aasebø U; Sundstrøm S
    J Clin Oncol; 2009 Jul; 27(19):3217-24. PubMed ID: 19433683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trial.
    Zatloukal P; Petruzelka L; Zemanová M; Kolek V; Skricková J; Pesek M; Fojtů H; Grygárková I; Sixtová D; Roubec J; Horenková E; Havel L; Průsa P; Nováková L; Skácel T; Kůta M
    Lung Cancer; 2003 Sep; 41(3):321-31. PubMed ID: 12928123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gemcitabine and metabolite pharmacokinetics in advanced NSCLC patients after bronchial artery infusion and intravenous infusion.
    Alharbi AF; Kratzke RA; D'Cunha J; Maddaus MA; Sanghavi K; Kirstein MN
    Cancer Chemother Pharmacol; 2019 Feb; 83(2):387-391. PubMed ID: 30542769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of gemcitabine and carboplatin in advanced non-small cell lung carcinoma.
    Gajra A; Mehdi SA; Kirshner J; Newman N; Graziano SL
    Lung Cancer; 2001 May; 32(2):189-96. PubMed ID: 11325490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized phase II study of carboplatin-paclitaxel or gemcitabine-vinorelbine in patients with advanced nonsmall cell lung cancer and a performance status of 2: West Japan Thoracic Oncology Group 0004.
    Saito H; Nakagawa K; Takeda K; Iwamoto Y; Ando M; Maeda M; Katakami N; Nakano T; Kurata T; Fukuoka M
    Am J Clin Oncol; 2012 Feb; 35(1):58-63. PubMed ID: 21293243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II study of carboplatin plus gemcitabine in advanced non-small-cell lung cancer (NSCLC): a hoosier oncology group study.
    Ng EW; Sandler AB; Robinson L; Einhorn LH
    Am J Clin Oncol; 1999 Dec; 22(6):550-3. PubMed ID: 10597737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.